About Drugs in Context

Drugs in Context is an open access, peer-reviewed, continuous publication of international standing. It is a member of the Directory of Open Access Journals (https://doaj.org/). It is listed on PubMed and all articles are free-to-view/download immediately on PubMed Central.

Latest rankings (SJR/Scimago 2019): equivalent Impact Factor = 3.56. Q2 title; H index = 15; SJR = 0.848. Ranked 15 of 80 open access pharmacology journals worldwide (based on eIF). Ranked 71 of 326 of all pharmacology journals worldwide (based on eIF).

Articles: we publish high-quality, peer-reviewed original research papers and topical review articles covering the latest evidence and innovations in drug treatment across all therapeutic areas. Other article types are considered.

Peer review: we conduct single-blind external peer review on all manuscripts with comments from at least two peer reviewers. Our aim is to obtain a first editorial decision within 3 weeks of manuscript submission and online publication within 3 weeks of acceptance.

Submit your manuscript: check the 'SUBMISSION' page for full instructions. Submit your manuscript via Manuscript Manager.

Latest Article

The multiple faces of ketamine in anaesthesia and analgesia

Silvia Natoli

Articles 2020

Ertugliflozin in the treatment of type 2 diabetes mellitus

Joel C Marrs PharmD, MPH, Sarah L Anderson PharmD

Acute bacterial sinusitis in children: an updated review

Alexander KC Leung MBBS, FRCPC, FRCP (UK and Irel), FRCPCH, FAAP, Kam Lun Hon MD, FAAP, FCCM, Winnie CW Chu MD, FRCR

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib

Novin Nezamololama, BSc, MSc, Keira Fieldhouse, BSc, Kristy Metzger, BSc, Melinda Gooderham, MD, MSc, FRCPC

Role of renin–angiotensin–aldosterone system inhibitors in heart failure and chronic kidney disease

Namrata Singhania MD, Saurabh Bansal MD, Shreya Mohandas, Divya P Nimmatoori MD, Abutaleb A Ejaz MD, Girish Singhania MD

Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients

Karel Pavelka MD PhD, Zoltán Szekanecz MD PhD DSc, Nemanja Damjanov MD PhD, Branimir Anić MD PhD, Matija Tomšič MD PhD, Vadim Mazurov MD PhD, Marija Maksimovic MD, Orsolya Nagy MD PhD, Jerzy Świerkot MD PhD, Tzvetanka Petranova MD PhD, Tiina Veldi MD, Asta Baranauskaitė MD PhD, Catalin Codreanu MD PhD, Daina Andersone MD PhD, Roy Fleischmann MD